We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Microvascular Dropout as a Potent Biomarker for Structural Progression in Glaucoma Suspects

MedXY Editorial Team•Mar 16, 2026•news
glaucomaMicrovascular DropoutOCTAOptic Nerve Head

High-Risk Indicators in Glaucoma Suspects: The Role of Microvascular Dropout

Identifying which glaucoma suspects will eventually progress to manifest glaucoma remains one of the most significant challenges in clinical ophthalmology. While intraocular pressure (IOP) remains the only modifiable risk factor, structural changes often precede functional loss by years. Recent research published in the American Journal of Ophthalmology by Soltani et al. provides compelling evidence that microvascular dropout (MvD) in the parapapillary region is a critical biomarker for structural optic disc progression, even in eyes that remain clinically stable by traditional perimetric standards.

Highlights

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Ultra-Widefield OCT Reveals Distinct Foveal and Optic Nerve Head Topography in Pathologic Myopia with Posterior StaphylomaAdvanced ultra-widefield OCT mapping elucidates spatial differences in foveal and optic nerve head positioning within posterior staphyloma of pathologic myopia, highlighting distinct remodeling processes and associations with axial length aSep 22, 2026Event-Based Progression Detection in Glaucoma: Integrating OCT, OCT Angiography, and Visual Field MetricsThis review synthesizes recent evidence on event-based progression detection in glaucoma, highlighting that OCTA vessel density may identify progression earlier than structural OCT or visual field testing, with important implications for clSep 9, 2026Long-Term Incidence and Risk Factors for Glaucoma: Insights from the Gangnam Eye Cohort StudyA 10-year Korean cohort study reveals that retinal arteriosclerosis, intraocular pressure, age, serum uric acid, and cholesterol levels significantly increase the risk of structural glaucoma conversion.Aug 31, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
IOP Stress Testing Identifies Glaucoma Eyes at Risk of Fast Progression Despite Controlled Office Pressure
A stress test measuring intraocular pressure identifies glaucoma patients at risk of rapid progression despite normal office pressure readings, offering complementary prognostic insights beyond routine checks.
Aug 28, 2026
Long-Term Efficacy and Visual Field Outcomes of Selective Laser Trabeculoplasty in Glaucoma ManagementThis study evaluates long-term outcomes of selective laser trabeculoplasty (SLT) in controlling intraocular pressure and preventing visual field deterioration, identifying clinical factors influencing effectiveness and progression risk.Aug 26, 2026
Impact of Trabeculectomy versus Medical Therapy on Visual Field and Quality of Life in Advanced Glaucoma: Insights from the TAGS StudyThe TAGS Study shows trabeculectomy slows visual field loss more effectively than medical treatment in advanced glaucoma, yet this did not translate into significant quality-of-life improvements over five years, highlighting limitations inAug 24, 2026